Invest in **GLOBAL** CONGLOMERATES

listed in India and reap the benefits of MNC Investing

ANANDRATHI



30th April, 2024

Objective & Investment Philosophy



Focus on consistency of return and risk moderation by investing in **Objective** Multinational Companies listed in India. WABCO GSK CONSUMER HIND UNILEVER **EROLAC** AMBUJA CEM BOSCH ABB6 COLGATE

Investments into listed companies in India in which the foreign shareholding is over 50% and/or the management control is bestowed in foreign company and/or the technological and managerial know-how brought in by foreign partner/investor.

4P Strategy – Stock Selection



Past Analysis

Business Moat /Market Share Operating efficiency Working Capital Management Balance sheet growth ROE And ROCE growth etc

Present Analysis

Current vs Historical Valuation, Margins, leverage, Asset Turnover Capacity and utilisation Capex and Cashflow

4P

Pedigree


Management Experience and Qualification Corporate Governance Practices Shareholding patterns

Potential

Sector Outook Favourable Macro Sufficient capacity Outstanding Order Book, Multi year Contract, Client Addition, Product Pipeline etc

Companies to undergo 4 P Analysis to make it to the Universe

Successful Business Model



- MNC's benefit from the economy of scales by spreading R&D expenditures and advertising costs over their global sales, pooling global purchasing power over suppliers, and utilizing their technological and managerial know-how globally with minimal additional costs.
- MNC's can use their global presence to take advantage of underpriced labor services available in certain developing countries, and gain access to special R&D capabilities residing in advanced foreign countries



Strong Corporate Governance



MNC's are generally rated high for their corporate governance standard.

MNC

PORTFO

- MNC's depict high transparency and accountability with well laid out policies and regulatory framework, internal control and risk management.
- This provide good comfort for an investor who would not fall prey to any negative impact on investment due to corporate mis-management and fraud.

Healthy Balance Sheet



High Operating Ratio

Most MNC's have better operating ratios compared to its peers, Operating margins would vary depending upon the sector it operates in.



Zero Debt or Low Debt Equity

Most MNC's are zero debt company or Very low on Debt Equity hence. Changes in Interest rate cycle do not affect these companies.

Positive Free Cash Flow

Operating free cash flow is positive in most of them, they are cash rich and regular dividend paying company.

Healthy Return Ratio

Return ratio like ROE and ROCE are also high compare to peer group in most cases. Investors benefit from share premium the share price command on sustain basis.




MNC companies during the holding period provides healthy dividend and capital appreciation by earnings growth and sometime carries an additional trigger for value appreciation in form of corporate actions like Open offers, Buybacks and Delisting etc. This usually add substantial appreciation to the share price enhancing investors ROI. Below are some illustrations of the same.

Sr.	Company	Corporate Action	Announcement date	Price before Announcement	Date	Price on closure of offer	% Gain
1	Fulford India	Delisting	25-Apr-14	682	30-Jul-15	2400	252%
2	Alfa Laval	Delisting	16-Sep-11	1965	12-Apr-12	4000	104%
3	HUL	Open Offer	29-Apr-13	497.6	04-Jul-13	600	21%
4	Glaxo Consumer	Open Offer	23/11/2012	3049	30-Jan-14	3900	28%
5	Siemens	Open Offer	28-Jan-11	727	13-Apr-11	930	28%

NIFTY MNC Index Analysis/Study



A study done on Nifty MNC Index which constitute 15 stocks shows favorable risk reward a portfolio of MNC company could deliver.




NIFTY MNC Index has good correlation with NIFTY 50 Index. However the Beta stands at 0.8

Annualized returns of NIFTY MNC Index is higher compared to NIFTY 50 Index and Volatility is lower. This shows a favorable risk reward for NIFTY MNC against NIFTY 50 Index

Note: The above study is done on Nifty MNC Index which constitute 15 stocks. The actual portfolio in PMS could deviate compared to NIFTY MNC Index. The above analysis is not an indicative of future performance.

Portfolio Strategy





Re-VIEW Strategy



Valuation Check

E

A constant check is kept on the valuation of the companies so that any stock whose valuation becomes relatively high, due to any reasons like sentiments or increase in liquidity, is exited before any price correction comes to the stock. We then shift the money to a new stock with a reasonable valuation.

Impact of Events

A stock price can be highly affected by an event or series of events, recent examples: COVID crisis, Russia-Ukraine War, Increase in Crude Price, Interest Rates Hike etc. Our team actively tracks these events and makes timely modifications as per the situation's needs to minimize risks & optimize returns.

Earnings Visibility Changes

Our fundamental research team scrutinizes the quarterly results of the companies to understand the current & future estimated growth. If we are not satisfied with 2 or 3 quarterly results of the company & don't see growth, we take an exit to move to another stock.

Weightage Check of the Holdings


Every stock & sector has been capped to a certain percentage of the total allocation to limit downside due to any uncertainties and also diversify the portfolio. If any stock or sector reaches near to the decided percent of allocation, we book profits and reduce the weightage and invest into any other stock.

Top Holdings and Allocation



Sr No	Top 10 Holdings	% Holdings
1	Siemens Ltd	11.9%
2	Maruti Suzuki India Limited	8.8%
3	ITD Cementation India Limited	8.2%
4	Schaeffler India Limited	7.1%
5	CRISIL Ltd	6.1%
6	KSB Limited	5.1%
7	Nestle India Ltd	5.0%
8	3M India Ltd	5.0%
9	Abbott India Ltd	4.8%
10	Ingersoll-Rand (India) Ltd	4.7%


Market Cap Allocation



Data as on 30th April, 2024


Avg Mkt C	ap (cr)	Abrasives	
Large Cap	344084	-	
Midcap	38545	ІТ	
Small Cap	10410	Assessminal	
Overall Portfolio	110383	Agrochemical	

The current model client portfolio comprise of 19 stocks. Portfolio is well diversified across market capitalization and sector. We have shown top 10 stocks based on current portfolio. Most of the stocks are given more or less equal and sizable weightage in portfolio



4 Years Past Performance Data as on 30th April, 2024






Consistent Performer



3 Years Rolling Returns




Our MNC PMS has been most consistent in terms of rewarding the investors if they had stayed invested with us for more than 3 years. Any such investor has made: 18% CAGR on an average, 25% CAGR on the maximum side, 10% CAGR on the minimum side.

Disclaimer: Past Performance is not necessarily indicative of likely future performance. Performance mentioned above are not verified by SEBI. We have shown the performance as Aggregate performance of all clients on TWRR basis. **Note**: - Returns above one year are annualized. Returns are net of all fees and expenses.

Portfolio Performance





14

Note: - Returns above one year are annualized. Returns are net of all fees and expenses.


Disclaimer: Past Performance is not necessarily indicative of likely future performance.

Performance mentioned above are not verified by SEBI. We have shown the performance as Aggregate performance of all clients on TWRR basis.

Portfolio Performance



Performance as on 30th April, 2024




Note: - Returns above one year are annualized. Returns are net of all fees and expenses.

Disclaimer: Past Performance is not necessarily indicative of likely future performance. Index 15**BSE 500 TRI** is shown as per guidelines Performance mentioned above are not verified by SEBI. We have shown the performance as Aggregate performance of all clients on TWRR basis.

Top Contributors *Data as on 30th April, 2024*







PORTFOLIO STRATEGY

Selection Process





Improving ROCE and ROE

Networking Capital / Sales, Asset Turnover Improving operating Efficiency

(Low Debt Equity and Positive Free Cash Flow) Strong Balance sheet

90 Approx MNC Company

Out of 4500 listed Company, there are only 90 odd MNC Companies which are own by Foreign Promoter with more then 1000 cr Market Cap which make the stock universe limited for further evaluation.

Well Balanced Defensive but Growth




Consumer non Discretionary	 Staple and Healthcare Companies Like Hindustan Unilever, Nestle, Britannia, Colgate, Glaxo Consumer etc. Pfizer, Abbot lab, Glaxo Pharma, Sanofi, Astrzenca.
Consumer Discretionary	 Auto, Paint, Consumer Durables etc Maruti, Wabco, 3M India, Bata, Whirpool, Bosch, Johnson Hitachi, Kansai Nerloac, Akzo Nobel, Castrol, Gulf oil Lubricant etc.
Cyclical	 Cement, Engineering, Electricals, Capital Goods, Metals, IT, Chemicals etc. ACC, Ambuja, Heidelberg, Simenes, ABB, Honeywell,
/Others	Grindwell Norton, GMM Pfaudler, Mphasis, Bayer Crop, BASF, Oracle Financial, Crisil, Schaeffler, SKF etc.

The three bucket strategy with shifting allocation as per the market outlook help to further optimize the returns, However Consumables remains the core part of the portfolio.


Growth like Multicap but Quality like Large Cap

- MNC PMS is a Multicap Portfolio with all market capitalization. (large, Mid, Small)
- There are many companies which by Indian Market Cap Definition are called as Midcap Companies where as by Global Definition these are Large cap.
- One gets benefit of growth like Midcap Companies in India where as Quality of Large Cap. Few Eg given below

POR'







Gain on Open Position

Partial Profit Booking *GMM Pfaudler has been totally exited

Though we have kept single stock weight max 15%, Partial Profit booking is done whenever overall weight of single stock in portfolio reaches close to 9-10% of portfolio.

Max 15% weight is kept in case of any special opportunity is going to get unfold in short term.

Average Annual Turnover 30%

Partial Profit booking and Stocks completely exited in profit is shown in adjacent table.

To optimize performance there are couple of partial and complete exits in losses done depending upon market dynamics.

Eg: Reducing allocation in Auto and Ancillary in 2018-19 where sector was going through challenges


Eg 2: Covid 19. Reducing allocation in Industrial and cyclical

Success Stories - Abbott India



Abbott India

- Strong Parentage : Abbott Laboratories USA
- Offering high-quality trusted medicines in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders and primary care.
- Key Brands : Duphaston, Thyronorm, Udiliv, Digene, Cremaffin, Duphalac
- Balance Sheet Strength: Zero Debt, Positive Cash Flow and ROE Maintained above 20% over last 5 years




- Focus strategy
 - 1) to accelerate key brands
 - 2) Drive therapy leadership
 - 3) Strengthen Multi-channel and insight driven marketing
 - 4) Identify new product opportunity
 - 5) Focus on talent development and engagement
 - 6) 100+ products Launch in last 10 years and more launches in coming years.

Success Stories - GMM Pfaudler



GMM Pfaudler

- Foreign Promoter: Pfaudler Inc.
- A leading supplier of glass lined based equipment (reactors, storage tanks) in India, commanding > 50% domestic market share, finding critical application in the chemical & pharmaceutical industries.
- Benefit from Domestic Chemical, Pharma and Agrochemical capacity addition post Shut down of industries in China.
- Balance Sheet Strength: Zero Debt, Positive Cash Flow and ROE Maintained above 20% over last 5 years.



- Focus strategy
 - 1) to accelerate key brands
 - 2) Drive therapy leadership
 - 3) Strengthen Multi-channel and insight driven marketing
 - 4) Identify new product opportunity
 - 5) Focus on talent development and engagement
 - 6) 100+ products Launch in last 10 years and more launches in coming years.

Success Stories - Coforge Ltd.



Coforge Ltd.

- In 2019 NIIT ltd sold its stake in NIIT Technology to foreign player Barings. The company rebranded to name it COFORGE ltd.
- Over the Last 5 years Revenues for the company has grown by 10% plus CAGR and PAT has grown by 25% plus CAGR.
 Operating margin is maintained around 17% throughout.
- The company has three key verticals Banking and Financial contributing (17%), Insurance (30%), Travel and Transportation (29%) and Others (24%). Geography wise America contributes 48%, EMEA 37%, ROW 15%. In terms of service Mix ADM Contributes 73%, IMS 16% and IP Based 6% and others.



 Despite COVID except for Travel business most business is doing good with constant addition of new clients especially healthcare. Company continues to remain confident about its near- medium-term growth prospects, citing its strong order booking/pipeline and its investments in building strong sales and leadership.

Founder & Promoter (Anand Rathi Group)





Anand Rathi Founder & Chairman management consultancy.

Gold medalist Chartered Accountant having more than four decades of rich and varied

experience in corporate management, financial & capital markets and corporate &

Served Aditya Birla Group at very senior positions for more than 25 years before starting his own financial services outfit. Shri Rathi was earlier President of BSE for two terms.

Anand Rathi Group derives its strength and vision from legendary leadership of Shri Anand Rathi and charting growth path in his able guidance.



Over twenty years broad based experience in the securities market and key driver of the Retail and Institutional Equities business of the group.

Under his leadership, the Group's Institutional & Retail Business has won great recognition and many accolades. He has played a pivotal role in the Group's network expansion and pan India growth.

His valuable contribution towards professionalizing the management of the Group has won him immense respect from the corporate world.

Pradeep Gupta Co Founder & Vice Chairman





Mayur Shah Fund Manager

More than 18 years of rich experience in Investment advisory, Product Development and Portfolio Management.

Working with Anand Rathi since 2007 across Portfolio Management and Private Client Group Equity Advisory.

Started Career with "Kotak Securities Ltd" in 2005 as an Investment Advisor subsequently got into developing Equity products and running the same.

Qualified MBA (Finance) from Mumbai University and Certified Financial Planner.



More than 18 years of rich experience in Investment advisory, Portfolio Management and research.

Worked in past with Standard Chartered Securities, Religare Securities, Enam Securities.

PGDBM from Mumbai.

Vinod Vaya



MNC Portfolio

Minimum investment

Portfolio:

Themes offered

Risk – reward & tenure

Type of instruments

Benchmark

Rs. 50 lakhs

15-20 STOCKS, diversified across sectors.

Diversified portfolio of Multinational Companies listed in India with controlling stake with foreign holder

Moderate risk reward. Investment tenure preferably 3 years+

Equity & Equity Related Instruments, Fixed Income Instruments, Cash & Cash Equivalent

BSE 500 TRI

Benefits

- Dedicated Web Login for client to monitor portfolio.
- A relationship manager to cater to investment needs
- Constant monitoring of the portfolio
- Audited statement at year end for tax filing purpose. **Support**
- Back office customer service desk to address client queries

Fees & Charges

- AMC fees : 2.5% p.a (Charged Pro-rata at end of each quarter)
- Brokerage : 0.25% on Equity delivery transaction
- Exit Load : 2% 1st Year, 1% 2nd Year, NIL after 2nd Year
- Other Charges : GST, Other charges levied by Exchange, Custodial charges (3 bps) levied by custodian and any other statutory charges.



Specific Disclaimer

All Investment are subject to Market Risk.

Please read the risk factors before investing in the same.

Past Performance is not necessarily indicative of likely future performance

Registration Details		Direct On-Boarding
PMS registered under PMS Registration Numbe Custodian	: Anand Rathi Advisors Ltd. : INP00000282. : Orbis Financial Corporation Ltd.	To invest directly into our PMS, please: Mail: pmsdesk@rathi.com Contact: 022-62813851, 52 Or click here: https://www.anandrathipms.com/contact-us.php
Product Support Name : Vinod Vaya	Back Office Support Name : Sheetal Kotian / Sourabh	More Information Visit Our Website: https://www.anandrathipms.com
Tel : 022 - 6281 3851 Email ID : vinodvaya@rathi.com	Tel : 022 – 6965 3015 / 3014 Email ID : pmsoperations@rathi.com	Click here for Disclosure Document

OFFICIAL ADDRESS: 10th Floor, Express Zone - A Wing, Western Express Highway, Malad (East), Mumbai - 400063, India

BOARD LINE : +91 22

:+91 22 6281 7000

THANK YOU

ANANDRATHI A D V I S O R S L I M I T E D

Disclaimer:-This presentation has been issued by Anand Rathi Advisors Limited (ARAL), which is regulated by SEBI. Neither the information nor any opinion expressed constitutes an offer, or an invitation to make an offer, to buy or sell any securities or any options, futures or other derivatives related to such securities ("related investments"). ARAL and its affiliates may trade for their own accounts as market maker / jobber and/or arbitrageur in any securities of this issuer(s) or in related investments, and may be on the opposite side of public orders. ARAL, its affiliates, directors, officers, and employees may have a long or short position in any securities of this issuer(s) or in related investments banking or other services for, or solicit investment banking or other business from, any entity mentioned in this report. This presentation is prepared for private circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in this report and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities, if any, may fluctuate and that each security's price or value may rise or fall. Past performance is not necessarily a guide to future performance. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related investment mentioned in this report.